288 related articles for article (PubMed ID: 9472836)
1. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study.
Wetzel H; Anghelescu I; Szegedi A; Wiesner J; Weigmann H; Härter S; Hiemke C
J Clin Psychopharmacol; 1998 Feb; 18(1):2-9. PubMed ID: 9472836
[TBL] [Abstract][Full Text] [Related]
2. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial.
Szegedi A; Anghelescu I; Wiesner J; Schlegel S; Weigmann H; Härtter S; Hiemke C; Wetzel H
Pharmacopsychiatry; 1999 Jul; 32(4):148-53. PubMed ID: 10505485
[TBL] [Abstract][Full Text] [Related]
3. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients.
Lu ML; Lane HY; Chen KP; Jann MW; Su MH; Chang WH
J Clin Psychiatry; 2000 Aug; 61(8):594-9. PubMed ID: 10982203
[TBL] [Abstract][Full Text] [Related]
4. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight.
Hinze-Selch D; Deuschle M; Weber B; Heuser I; Pollmächer T
Psychopharmacology (Berl); 2000 Apr; 149(2):163-9. PubMed ID: 10805611
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial.
Anghelescu I; Szegedi A; Schlegel S; Weigmann H; Hiemke C; Wetzel H
Eur Neuropsychopharmacol; 1998 Dec; 8(4):315-20. PubMed ID: 9928923
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.
Lu ML; Lane HY; Lin SK; Chen KP; Chang WH
J Clin Psychiatry; 2004 Jun; 65(6):766-71. PubMed ID: 15291653
[TBL] [Abstract][Full Text] [Related]
7. [Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine: four case reports].
Papetti F; Morel-Pingault V; Buisse V; Maziere L; Banayan M; Thauby S; Besnard T; Darcourt G; Pringuey D
Encephale; 2007 Oct; 33(5):811-8. PubMed ID: 18357853
[TBL] [Abstract][Full Text] [Related]
8. Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study.
Lu ML; Chen TT; Kuo PH; Hsu CC; Chen CH
Schizophr Res; 2018 Mar; 193():126-133. PubMed ID: 28688742
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
Carrillo JA; Ramos SI; Herraiz AG; Llerena A; Agundez JA; Berecz R; Duran M; Benítez J
J Clin Psychopharmacol; 1999 Dec; 19(6):494-9. PubMed ID: 10587283
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer.
Joos AA; König F; Frank UG; Kaschka WP; Mörike KE; Ewald R
Pharmacopsychiatry; 1997 Nov; 30(6):266-70. PubMed ID: 9442550
[TBL] [Abstract][Full Text] [Related]
11. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
[TBL] [Abstract][Full Text] [Related]
12. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers.
Wang CY; Zhang ZJ; Li WB; Zhai YM; Cai ZJ; Weng YZ; Zhu RH; Zhao JP; Zhou HH
J Clin Pharmacol; 2004 Jul; 44(7):785-92. PubMed ID: 15199083
[TBL] [Abstract][Full Text] [Related]
13. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline.
Spina E; Avenoso A; Salemi M; Facciolá G; Scordo MG; Ancione M; Madia A
Pharmacopsychiatry; 2000 Nov; 33(6):213-7. PubMed ID: 11147928
[TBL] [Abstract][Full Text] [Related]
14. Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
Andrade C
J Clin Psychiatry; 2012 Nov; 73(11):e1362-4. PubMed ID: 23218164
[No Abstract] [Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
Baumann P
Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
[TBL] [Abstract][Full Text] [Related]
16. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
[TBL] [Abstract][Full Text] [Related]
17.
Boyle K; Cornett S; Fijtman A; Hunt-Harrison T
J Child Adolesc Psychopharmacol; 2021 Sep; 31(7):514-515. PubMed ID: 34166111
[No Abstract] [Full Text] [Related]
18. Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features.
Strous RD; Patel JK; Zimmet S; Green AI
Am J Psychiatry; 1999 Jun; 156(6):973-4. PubMed ID: 10360153
[No Abstract] [Full Text] [Related]
19. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder.
Dannon PN; Iancu I; Lowengrub K; Gonopolsky Y; Musin E; Grunhaus L; Kotler M
Clin Neuropharmacol; 2007; 30(6):326-34. PubMed ID: 18090457
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors.
Centorrino F; Baldessarini RJ; Frankenburg FR; Kando J; Volpicelli SA; Flood JG
Am J Psychiatry; 1996 Jun; 153(6):820-2. PubMed ID: 8633698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
